Neoantigen-based Cancer Immunotherapy Development Services

With our comprehensive neoantigen-based technologies, Creative Biolabs has established a premiere platform for the development service of neoantigen-based cancer immunotherapies.

Introduction of Neoantigen-based Cancer Immunotherapy

The neoantigen-based immunotherapies mainly include TCR-T, CART, bispecific antibodies, and various cancer vaccines (see Fig.1). Neoantigen-based agents in immunotherapies generally have a number of advantages. They could stimulate strong immune responses and keep long-term persistence with low-cost production and good tumor specificity. Therefore, neoantigen-based immunotherapies are regarded as one most promising strategy in the future.

Fig.1 Neoantigen-based therapies.¹

Hardships for Neoantigen-based Cancer Immunotherapy

• The identification of candidate neoantigens is resource-consuming and labor-intensive, and the project cycle may take weeks to convert the results into clinical applications.
• The identification accuracy of neoantigens is strongly dependent on the analytical depth and algorithms, which makes it difficult to avoid the inherent error rates.
• Unprofessional sample preparation, library construction, and low cell transfection efficiency may preclude the identification of potential neoantigens.

Neoantigen-based Cancer Immunotherapy Service at Creative Biolabs

Creative Biolabs has a comprehensive technical platform to support the research of immunotherapies based on neoantigens. From neoantigen identification to immunogenicity assessment and functional analysis, we offer one-stop and customizable services to help solve bio-technical problems about neoantigens. To learn more detailed information about our service, please click the service you are interested in below:

Neoantigen-based Cancer Immunotherapy Development

Key Technologies Associated with The Neoantigen-based Platform

• In silico prediction and prioritization of neoantigens
• Isolation, expansion, and stimulation of immune cells.
• Construction of peptide-pulsed APCs and TCR-transduced T cells.
• Immunogenicity assessment of neoantigens.
• Affinity, stability, and specificity assessment of the neoantigen and specific TCRs.
• In vitro and in vivo functional assessment of neoantigen-specific TCRs.

Neoepitope-specific T Cell Isolation Service

Research has shown that adoptive cell therapy (ACT) with neoantigen-specific T cells has demonstrated remarkable clinical responses.

Neoepitope-specific T Cell Isolation Service at Creative Biolabs facilitates a more rapid pace in your research. We achieve this by providing high-quality, enriched neoantigen-specific T cells. Through the integration of advanced MHC multimer platforms and deep expertise in T cell immunobiology, Creative Biolabs offers a targeted solution to a key limitation in cancer immunotherapy research.

The isolation of functional, neoantigen-specific T cells remains a major barrier to progress in this field. Our approach directly addresses this challenge-enabling precise recovery of high-purity T cells and thereby facilitating the development of personalized immunotherapeutic strategies.

Why Creative Biolabs?

Being a pioneer in the bioindustry, we offer services for neoantigen identification, immunogenicity assessment, and functional analysis of neoantigen-specific TCR. Our features and benefits are listed below:

• Professional knowledge of neoantigen-mediated immunotherapy.
• High-throughput candidate neoantigen screening with scientific data analysis.
• Comprehensive functional analysis for neoantigen-specific TCR.
• Integrated solution based on multiple methods to offer customized neoantigen-associated services.
• Various bioinformatics software combined with sequencing analysis for the prioritization of candidate neoantigens.
• Up-to-date technology tools and a technical team for the development of neoantigen-based cancer immunotherapy.

Creative Biolabs provides a one-stop platform to customize our services to meet the special needs of our clients. With a team of experts, we are confident and pleased to offer you satisfactory service during the project.

Reference

1. Xie, Na, et al. "Neoantigens: promising targets for cancer therapy." Signal Transduction and Targeted Therapy 8.1 (2023): 9. Distributed under Open Access license CC BY 4.0, without modification.

Download our brochure